$ERAS News

Erasca (ERAS) Stock Looks Above Fair Value After Its 5x Run

Erasca, Inc.: The Discount RevMed?

Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

B of A Securities Maintains Neutral on Erasca, Raises Price Target to $20

Guggenheim Maintains Buy on Erasca, Raises Price Target to $21

HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $22

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate

Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Morgan Stanley Maintains Equal-Weight on Erasca, Raises Price Target to $21

Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?

Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers